Byetta, Januvia/Janumet and Victoza

As we have previously reported, safety concerns regarding incretin mimetics such Byetta, Januvia/Janumet and Victoza, have lead to hundreds of lawsuits being filed across the country. Reports suggest that people taking the medications, Januvia and/or Byetta, for the treatment of Type 2 diabetes may be at an increased risk to develop pancreatitis or pancreatic cancer.

The United States Judicial Panel on Multi-District Litigation (MDL) is scheduled to meet on Thursday, July 25, 2013, in Portland, Maine, to hear arguments to decide whether the cases, known as IN RE: INCRETIN MIMETICS PRODUCTS LIABILITY LITIGATION, should be given MDL treatment. Granting MDL treatment will consolidate all federal lawsuits filed across the U.S. into one centralized district. This consolidation will streamline the pretrial discovery process, allowing the parties to avoid duplicative discovery and inconsistent rulings from different judges.

If granted, the MDL will likely be venued in the Southern District of California where Judge Anthony J. Battaglia is already overseeing a number of these cases. Plaintiffs have alleged that the manufacturers knew of the cancer risk associated with the incretin mimetics, but failed to disclose it to the medical community and/or consumers. It is expected that there could eventually be thousands of plaintiffs nationwide.

If you or a loved one have suffered from pancreatitis or pancreatic cancer after taking Byetta, Januvia/Janumet or Victoza, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any potential claims.

As we have previously reported, research has shown that several incretin mimetic pharmaceuticals may cause substantial injury in Type II diabetes patients. Incretin mimetic drugs help regulate blood sugar by stimulating insulin production by the pancreas.

 The April 8, 2013, edition of the Journal of the American Medical Association Internal Medicine (“JAMA”) published a study involving incretin mimetics, including Januvia and Byetta. The study reviewed administrative databases in the United States from 2005 until 2008, and concluded that there were “increased odds of hospitalization for acute pancreatitis” among uses of Januvia and Byetta.” The safety of these incretin mimetics has been the subject of recent studies and evaluations from the medical community and the Food and Drug Administration (“FDA”).

If you feel you have experienced any side-effects from taking Byetta, Januvia/Janumet or Victoza, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the Byetta, Januvia/Janumet or Victoza manufacturers.

As we have previously reported, research has shown that several incretin mimetic pharmaceuticals, such as Byetta, Januvia/Janumet and Victoza, may cause substantial injury in Type II diabetes patients. Incretin mimetic drugs help regulate blood sugar by stimulating insulin production by the pancreas.

Doctors have expressed concern about these drugs and their connection between pancreatitis, pancreatic cancer and thyroid cancer. The Food and Drug Administration (“FDA”) is meeting with members at the National Institutes of Health this month, June 2013, to discuss the risks associated with these medications. Reuters reports that the manufacturers of these drugs agree that an independent study is needed to better understand the link between the medicine and pancreatic cancer. The American Diabetes Association has also expressed concern with the link between these drugs and pancreatic cancer and agrees that an independent study is needed.

If you feel you have experienced any side-effects from taking Byetta, Januvia/Janumet or Victoza, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the Byetta, Januvia/Janumet or Victoza manufacturers.

As we have previously reported, litigation regarding incretin mimetics, such as Byetta, Januvia/Janumet and Victoza, continues to grow across the country. Byetta (Exenatide), manufactured by Amylin Pharmaceuticals, in association with Eli Lilly and Co., entered the market in 2005 for the treatment of Type 2 diabetes.  Byetta, now sold by Bristol-Myers Squibb and AstraZeneca, is a type of incretin mimetic that is administered as a subcutaneous injection of the abdomen, thigh or arm within 60 minutes of a person’s first and last meal of the day (i.e. two injections a day).

Dr. Peter Butler, the former head of endocrinology at the University of California at Los Angeles (UCLA) and former editor of the American Diabetes Association journal has advised that Byetta may be unsafely tied to pancreatic cancer. The resource center, DrugRisk, recently added a 2011, study from the UCLA that indicated use of Byetta could increase the risk of pancreatic cancer by 290% and thyroid cancer by 473%.  As the New York Times reports, Dr. Butler, believes that the seriousness of these risks was not received by the FDA at the time of testing. Dr. Butler worries that the use of very young animals, not as prone to pancreatic cancer, could have skewed the results and subsequent knowledge of the danger.

If you feel you have experienced any side-effects from taking Byetta, Januvia/Janumet or Victoza, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the Byetta, Januvia/Janumet or Victoza manufacturers.

Researchers at Johns Hopkins University have recently determined that a number of incretin mimetic diabetes medications like Byetta, Januvia/Janumet and Victoza could be linked to pancreatitis and pancreatic cancer.

A motion to consolidate the incretin mimetic cases into one MDL is currently pending. The Judicial Panel on Multidistrict Litigation (JPML) will likely hear oral argument, if necessary, this summer or fall.[1] If granted, the MDL will likely be venued in the Southern District of California where Judge Anthony J. Battaglia is already overseeing a number of cases. Plaintiffs have alleged that the manufacturers knew of the cancer risk associated with the incretin mimetics, but failed to disclose it to the medical community and/or consumers. Reports indicate there are approximately 500 cases ready for filing.  It is expected that there could eventually be thousands of plaintiffs nationwide.

If you feel you have experienced any side-effects from taking Byetta, Januvia/Janumet or Victoza, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the Byetta, Januvia/Janumet or Victoza manufacturers.

 


[1] One report indicates that the defendant manufacturers have consented to MDL status in the Southern District of California.

There are an estimated 25 million people in the United States with diabetes with an estimated $245 billion a year in diabetes-related health costs.  A number of drugs have been introduced to treat diabetes patients and time has shown that certain types of these drugs can cause substantial injury.

Byetta (Exenatide), manufactured by Amylin Pharmaceuticals, in association with Eli Lilly and Co., entered the market in 2005 for the treatment of Type 2 diabetes. Byetta is a type of incretin mimetic that is administered as a subcutaneous injection of the abdomen, thigh or arm within 60 minutes of a person’s first and last meal of the day (i.e. two injections a day). Byetta is widely prescribed and made $710 million in 2010 and is expected to surpass $1 billion in sales by 2015.

Januvia/Janumet (Sitagliptin) was developed and marketed by Merck & Co. as an oral anti-hyperglycemic beginning in 2006.  It is an enzyme-inhibiting drug that helps control blood sugar levels in Type 2 diabetics. Januvia generated sales of more than $4 billion last year alone.

Victoza (Liraglutide), developed and manufactured by Novo Nordisk, was approved for sale and use in January 2010 for the treatment of Type 2 diabetes. Victoza is a type of incretin mimetic that is administered as a once-daily injection. It has enjoyed strong market support, selling an estimated $1 billion in 2011. Sales reached nearly $750 million in the first half of 2012.

Recently, researchers at Johns Hopkins University determined that these medications could be linked to pancreatitis and pancreatic cancer, leading to an FDA warning. The FDA is currently working with the National Institute of Diabetes and Digestive Kidney Diseases and the National Cancer Institute to determine whether incretin mimetic medications should be pulled from the market altogether.

If you feel you have experienced any side-effects from taking Byetta, Januvia/Janumet or Victoza, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the Byetta, Januvia/Janumet or Victoza manufacturers.